BIOMARIN PHARMACEUTICAL INC Research and Development Asset Acquired Other than Through Business Combination, Written-off
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $220.96 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2026-02-26
- BIOMARIN PHARMACEUTICAL INC research and development asset acquired other than through business combination, written-off for the quarter ending 2025-12-31 was $0.00.
- BIOMARIN PHARMACEUTICAL INC research and development asset acquired other than through business combination, written-off for the quarter ending 2024-12-31 was $0.00.
- BIOMARIN PHARMACEUTICAL INC research and development asset acquired other than through business combination, written-off for fiscal 2025 was $220.96M.
- BIOMARIN PHARMACEUTICAL INC research and development asset acquired other than through business combination, written-off for fiscal 2024 was $0.00.
- BIOMARIN PHARMACEUTICAL INC research and development asset acquired other than through business combination, written-off for fiscal 2023 was $0.00.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $220.96M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $220.96M 10-Q · filed 2025-10-28 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-10-28 | ||
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |